ABIGAIL RANDALL: Open Payments
NPI 1104443308 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$934 in 35 payments from 14 companies in 2025. Trend: 2023 $135 · 2024 $246 · 2025 $934
Food & beverage: $934
| Company | Payments | Amount |
|---|---|---|
| Biogen, Inc. | 2 | $142 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $128 |
| Vanda Pharmaceuticals Inc. | 5 | $124 |
| Neurocrine BioSciences, Inc. | 4 | $110 |
| Lundbeck LLC | 4 | $107 |
| E.R. Squibb & Sons, L.L.C. | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Noven Therapeutics, LLC | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
Products named: REXULTI, ZURZUVAE, CAPLYTA, INGREZZA, FANAPT, COBENFY, Auvelity, Xelstrym.
Industry payments across TN — which companies pay providers there.
